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IMPORTING A HEADACHE FOR
WHICH THERE’S NO MEDICINE:
WHY DRUG REIMPORTATION
SHOULD AND WILL FAIL
Devin Taylor*
INTRODUCTION
On Canusa Avenue houses on one side of the street are in
Canada while houses right across the street are in Beebe Plain,
Vermont. 1 When the Canadian residents of Canusa Avenue need
medication for high cholesterol they can purchase a ninety-day
supply of twenty milligram Lipitor for one hundred seventy
dollars. 2 On the other side of the street, the very same supply
costs the Vermont residents approximately three hundred thirty
dollars in the United States. 3
This astonishing price difference is illustrative of the realities
of the modern marketplace: United States citizens are paying
between 35% and 55% more for brand name prescription drugs
than people around the world. 4 Canada’s Patented Medicines
*
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1
Vermont v. Leavitt, 405 F. Supp. 2d 466, 469 (D. Vt. 2005).
2
Id.
3
Id.
4
Melicia Seay, Drug Importation: Health Policy Tracking Service Issue
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Price Review Board (“PMPRB”) estimated that Americans pay
67% more for brand name drugs than Canadians. 5 Additionally,
one estimate suggests that U.S. consumers would have saved
$59.7 billion had they purchased all their brand name
prescription drugs at Canadian prices in 2004. 6 In perspective,
that amount exceeds the combined gross national products of
Kuwait, Iceland and Jamaica. 7
The extreme price difference has created problems for
Americans who often ration drugs instead of taking the
prescribed dosage or choose between purchasing the drugs they
need and other necessities. 8 Understandably, many Americans
are upset about having to make these difficult choices, while
Canadian neighbors can purchase the very same drugs at a
fraction of the price.
This reality is especially frustrating considering many of
these drugs were manufactured in the United States and
produced by U.S. pharmaceutical companies. 9 Logically, this
outrage has turned to ingenuity as many Americans are buying
drugs from Canada to the dismay of the Food and Drug
Administration (“FDA”). 10 In 2003 “nearly five million
shipments, comprising about 12 million prescription drug
products with a value of approximately $700 million entered the
U.S. from Canada.” 11
The federal government needs to address soaring drug prices
in order to make prescription drugs affordable for the entire
Brief, Health Policy Tracking Service (Thomson West), July 10, 2006 at 1,
available
at
http://www.netscan.com/EG-NSCNFS-B02/HPTSFILES%
5CISSUEBRIEFS%5CDrug1460.pdf.
5
Id.
6
Vermont, 405 F. Supp. at 469.
7
Id.
8
See Montgomery County v. Leavitt, 445 F. Supp. 2d 505, 507 (D.
Md. 2006).
9
Seay, supra note 4, at 2.
10
Id.
11
HHS Task Force on Drug Importation, Report on Prescription Drug
Importation,
ix
(Dec.
2004),
http://www.hhs.gov/importtaskforce/
Report1220.pdf.
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citizenry. One potential course of action that has been the
subject of debate is drug reimportation. Drug reimportation
“involves people in this country buying American-made
prescription drugs from countries to which U.S. pharmaceutical
companies export their products, either by traveling there to buy
drugs or purchasing them through the mail.” 12 However, drug
reimportation from foreign countries is not the appropriate
solution to escalating drug prices.
This note will explore and identify the reasons that
meaningful drug reimportation legislation will not pass, as well
as the reasons that a reimportation plan would be unsuccessful.
Part I of this note will explore current federal statutes, including
state response to the perceived failings of the federal government
and litigation involving drug reimportation and the authority of
the Secretary of Health and Human Services (“HHS”) under the
Federal Food Drug and Cosmetics Act (“FDCA”). Part II deals
with the reasons for the drastic price differences between the
United States and Canada. Part III explores the FDA’s
regulatory regime and examines the dangers of bringing drugs
from foreign sources into the United States, as well as the steps
the FDA has taken to enforce the law. Part IV discusses State
experiences with drug reimportation and the shortcomings that
have been identified. Part V investigates the strength of the
pharmaceutical lobby, its resources and manpower as well as its
ability to get results that favor drug companies. Finally, Part VI
will explore the current state of the law and potential changes in
the future.
I. DRUG REIMPORTATION AND THE LAW
The federal government, through a series of statutes has
created a system that makes it impossible for prescription drugs
to be imported into the United States without the consent of the

12

Colleen Newvine, Conference explores pros and cons of drug
reimportation,
University
of
Michigan
News
Service
(2003),
http://www.umich.edu/~urecord/0304/Nov03_03/07.shtml.
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HHS Secretary. 13 The past three HHS Secretaries have refused
to allow drug reimportation 14 and courts have unequivocally
upheld the ability of the HHS Secretary to deny importation. 15
In response to rising drug costs and the federal government’s
current unwillingness to act, some state governments have
initiated importation programs for their citizens, creating tension
with federal agencies. 16 Ultimately this tension has surfaced in
litigation where courts have uniformly endorsed the authority of
the federal government in this matter. 17
A. Federal Law
The current law, under the FDCA, allows only drug
manufacturers to import prescription drugs that were originally
manufactured in the United States back into this country. 18
There are two exceptions to this rule: 19 (1) the HHS Secretary
has the ability to authorize importation for emergency use; 20 and
(2) importation may be allowed under the Medicare
Modernization Act’s (“MMA”) importation provision. 21 The
MMA has a provision authorizing the HHS Secretary to
“promulgate regulations” allowing importation of prescription
drugs into the United States from Canada. 22 Furthermore, the
MMA states that the HHS Secretary “may grant to individuals,
by regulation or on a case-by-case basis, a waiver of the
prohibition of importation of a prescription drug or device or
class of prescription drugs or devices, under such conditions as

13

See discussion infra Part I.A.
Id.
15
See infra Part I.C.
16
See infra Part I.B.
17
See infra Part I.C.
18
21 U.S.C. § 381(d)(1) (2006).
19
21 U.S.C. § 381(d)(2); Medicare Prescription Drug, Improvement and
Modernization Act of 2003, Pub. L. No. 108-173, § 804(b) (2003).
20
21 U.S.C. § 381(d)(2).
21
Pub. L. No. 108-73, § 804(b).
22
Id.
14
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the Secretary determines to be appropriate.” 23 For either of
these exceptions, the Secretary must certify to Congress that
implementation “will pose no additional risk to the public’s
health and safety; and result in significant reduction in the cost
of covered products to the American consumer.” 24
The MMA replaced the Medicine Equity and Drug Safety
Act of 2000 25 (“MEDS Act”), which likewise allowed the HHS
Secretary “to pass regulations allowing commercial importation
of prescription drugs.” 26 The MEDS Act also conditioned
importation on a certification to Congress by the HHS Secretary.
Neither former HHS Secretary Donna Shalala, under President
Bill Clinton, nor former Secretary Tommy Thompson, under
President George W. Bush, approved certification for any
prescription drug. 27 Likewise, current HHS Secretary, Michael
Leavitt, has refused to issue a certification under the MMA. 28
Moreover, the FDCA establishes a “closed” system where
“the FDA regulates the manufacture, marketing and labeling of
drugs sold in the United States.” 29 Any drugs not manufactured
according to the FDA’s current “good manufacturing practice”
(“cGMP”) per the FDCA are not allowed into interstate
commerce. 30 Unless a drug meets all U.S. packing, labeling and
dosage requirements it will not be approved, even if it is a
foreign version of an FDA approved drug. 31 Thus the FDCA is
designed to keep pharmaceutical drugs within the closed system,
monitored by the FDA.

23

Pub. L. No. 108-73, § 804(j)(2)(A).
Pub. L. No. 108-73, § 804(l)(1).
25
Medicine Equity and Drug Safety Act of 2000, Pub. L. No. 106-387
(2000).
26
Vermont v. Leavitt, 405 F. Supp. 2d 466, 474 (D. Vt. 2005).
27
Id.
28
Id.
29
Id. at 473.
30
21 U.S.C. § 351(a) (2006).
31
See 21 U.S.C. § 331(a),(d) (2006).
24
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B. State Response
Due to the federal government’s perceived inability to make
progress in reducing the price of prescription drugs, many state
governments have decided to enter the Canadian market. 32 Some
have even created websites linking to Canadian pharmacies so
that state residents can fill prescriptions at Canadian prices. 33 In
February 2004, Minnesota became the first to create such a
website, and by the end of the same year, eight other states had
followed. 34 Eleven states 35 and the District of Columbia now
have such websites. 36 Illinois Governor Rod Blagojevich has
been, perhaps, the most aggressive participant in the drug
reimportation debate. In 2004, Blagojevich and Wisconsin
Governor Jim Doyle started the I-SaveRx program 37 which
permits Illinois and Wisconsin residents access to less expensive
prescription drugs from Canada, Ireland and the United
Kingdom via a website and telephone number. 38 The program
utilizes CanaRx, “a pharmacy benefits manager that operates a
network of online pharmacies,” 39 to offer drug information from
nearly sixty pharmacies in Canada, Ireland and the United
Kingdom for approximately one hundred twenty commonly
prescribed drugs. 40
Prior to the unveiling of I-SaveRx, Blagojevich

32

Seay, supra note 4, at 5.
Id.
34
Id.
35
Minnesota, Wisconsin, New Hampshire, North Dakota, Rhode Island,
Illinois, Washington, Missouri, Vermont, Nevada and Kansas offer access to
imported drugs to their residents via the internet. Melicia Seay, Drug
Importation: Health Policy Tracking Service Issue Brief, Health Policy
Tracking Service (Thomson West), Jan. 8, 2007 at 6, available at
http://www.netscan.com/EG-NSCNFS-B02/HPTSFILES%5CISSUEBRIEFS
%5CDrug1680.pdf.
36
Id.
37
http://www.i-saverx.net/
38
Seay, supra note 4, at 5-6.
39
Id. at 6.
40
Id.
33
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commissioned a study on the potential cost savings associated
with drug reimportation. 41 The results of the study indicated that
the state could develop a system with “safety checks equal to or
greater than Illinois’ current pharmaceutical system and achieve
savings of up to $90.7 million.” 42 In fact Blagojevich said “we
suspected that the Canadian procedures for distributing, labeling
and handling prescription drugs were safe, but we didn’t expect
them in some cases to be even safer than the procedures we use
here in the United States.” 43 Additionally Blagojevich charged,
“it’s time the FDA stops protecting the big drug companies, it’s
time they start helping people.” 44
However, a major problem with these state initiatives is that
they may be unreliable. For example, during the first two weeks
of February 2005, only a few months after the launch of ISaveRx, the FDA blocked over 25% of the shipments from
Canadian pharmacies to U.S. consumers purchased thru the ISaveRx program. 45 The FDA maintains that current law, under
the FDCA, allows only drug manufacturers to import
prescription drugs that were originally made in the United
States. 46 According to the FDA, “the law was designed to
facilitate a closed drug distribution system to ensure that the
domestic drug supply is safe and effective.” 47 Although the
FDA has not yet initiated a lawsuit against any of the states, the
FDA has seized shipments from Canada intended for U.S.
consumers. 48 Thus this conflict may create disincentives to
41

Press Release, Office of the Governor, Blagojevich releases muchanticipated report on feasibility and savings of prescription drug importation
(Oct. 27, 2003) (on file with author), http://www.illinois.gov/
PressReleases/ShowPressRelease.cfm?SubjectID=3&RecNum=2346.
42
Id.
43
Id.
44
Id.
45
Seay, supra note 4, at 6.
46
Id. at 1.
47
Id.
48
Id. at 6 (citing that “during the first two weeks of February 2005, the
FDA blocked more than 25 percent of prescription drug shipments purchased
by U.S. residents from Canada through the I-SaveRx program.”).

DEVIN.DOC

1428

7/1/2007 11:05 PM

JOURNAL OF LAW AND POLICY

utilize the programs.
Additionally, the state solution is inadequate because
consumers in thirty-nine states do not have access to such
programs. 49 Many state governors oppose programs such as ISaveRx because they violate federal law, but others are
distressed by the fact that initiating such programs could make
the state liable for its failings. 50 After vetoing a series of bills
approved by the California state legislature that would have
created a web site linking California residents to Canadian
pharmacies, California Governor Arnold Schwarzenegger 51 said:
“Importing drugs from Canada or assisting residents in their
efforts to do so would violate federal law and could expose the
state to civil, criminal and tort liability.”52 Therefore, while
state action has been influential in bringing the concerns
surrounding drug reimportation to the foreground, it has not
yielded permanent solutions that can be enjoyed by the entire
citizenry.
C. Judicial Review
By including provisions for the possibility of drug
reimportation, the MMA may have provided hope for those in
favor of reimportation. However, in practice these provisions
have achieved little since courts have given great deference to
the findings of the HHS Secretary and have been unwilling to
subject the Secretary’s findings or the FDA’s enforcement to

49

Id. at 7.
Seay, supra note 4, at 8.
51
In 2006, Governor Schwarzenegger changed his position, writing a
letter asking Congress to relax federal barriers to buying drugs from foreign
countries. Critics have speculated that Schwarzenegger’s new position is
political posturing and not his true feelings on the issue. Melicia Seay, Drug
Importation: Health Policy Tracking Service Issue Brief, Health Policy
Tracking Service (Thomson West), Oct. 2, 2006 at 14, available at
http://www.netscan.com/EG-NSCNFS-B02/HPTSFILES%5CISSUE
BRIEFS%5CDrug1558.pdf.
52
Id. at 8.
50
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judicial review. 53 In United States v. Rx Depot, Inc. 54 the
United States District Court of Oklahoma supported the FDA’s
finding that Rx Depot was illegally importing drugs from
Canada. Meanwhile, in both Vermont v. Leavitt 55 and
Montgomery County v. Leavitt, 56 courts upheld the discretion of
the HHS Secretary in granting or denying states’ waivers
allowing drug importation. 57
In Rx Depot, the United States District Court of Oklahoma
issued an injunction against Rx Depot, Inc., an organization
operating to assist U.S. citizens in purchasing drugs from
Canada. 58 This organization had nearly 85 storefronts
throughout the United States and served around 800 customers
per day. 59 Customers were able to mail or fax their medical
history, a prescription and other documents to one of the
storefronts, and an employee would then send the information
and the customer’s credit card information to a Canadian
pharmacy. 60 A Canadian doctor would then write a new
prescription which would be filled in Canada and shipped to the
U.S. customer. 61 The owners of Rx Depot would receive
between a ten and twelve percent commission on each order. 62
The court affirmed the FDA’s finding that this organization
violated U.S. law each time it imported prescription drugs from
Canada. 63 Moreover the court supported the FDA’s use of
53

Andrews v. United States Dep’t of Health and Human Services, 2005
U.S. Dist. LEXIS 5710, at 9 (D.D.C. 2005); Vermont v. Leavitt, 405 F.
Supp. 2d 466, 475 (D. Vt. 2005); Montgomery County v. Leavitt, 445 F.
Supp. 2d 505, 513 (D. Md. 2006).
54
290 F. Supp. 2d 1238, 1252 (N.D. Okla. 2003).
55
Vermont v. Leavitt, 405 F. Supp. 2d 466 (D. Vt. 2005).
56
Montgomery County v. Leavitt, 445 F. Supp. 2d 505 (D. Md. 2006).
57
405 F. Supp. 2d at 474; 445 F. Supp. 2d at 512.
58
Rx Depot, 290 F. Supp. 2d 1238, 1240.
59
Id. at 1240.
60
Id. at 1240-41.
61
Id. at 1241.
62
United States v. Rx Depot, 290 F. Supp. 2d 1238, 1241 (N.D. Okla.
2003).
63
Id. at 1245.
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discretion in selectively enforcing illegal drug reimportation due
to the Agency’s limited resources. 64
Additionally, courts have denied states the opportunity to
legally import drugs into the U.S. 65 In Vermont v. Leavitt, the
state of Vermont brought suit against HHS Secretary Michael
Leavitt because Leavitt denied Vermont’s petition to initiate a
state run importation program in which prescriptions would be
forwarded to a “Canadian firm where the prescription would be
reviewed by a physician familiar with the member’s medical
history and re-written as a Canadian prescription, which would
be forwarded to a licensed Canadian pharmacy to be filled and
sent by mail to the member in the United States.” 66 The impetus
for the lawsuit was Vermont’s concerns about the number of
citizens already importing drugs from nearby Canada and the
safety of individual citizens bringing home drugs from across the
border. 67 The state believed that it would be better equipped to
deal with the safety issues than individual citizens and
complained that the state does not “have the opportunity to
intervene to minimize the risks associated with prescription
medications obtained outside the U.S.” 68
The Vermont court agreed with the court in Rx Depot 69 that
this is an issue for Congress, saying “to the precise question at
issue,” 70 the court “must give effect to the unambiguously
expressed intent of Congress.” 71 In interpreting the intent of
Congress, the court did not equivocate, saying “[g]iven the
legislative history, it is difficult to escape the conclusion that
Congress expected the importation provisions of the MMA
64

Id. at 1249 (finding that this ruling was in response to RxDepot’s
claim that the FDA was being “unconstitutionally selective” in its
enforcement of the FDCA).
65
Vermont v. Leavitt, 405 F. Supp. 2d at 470.
66
Id. at 471.
67
Id.
68
Id.
69
United States v. Rx Depot, 290 F. Supp. 2d 1238, 1245 (N.D. Okla.
2003).
70
Vermont v. Leavitt, 405 F. Supp. 2d at 470.
71
Id.
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would never be implemented.” 72 In finding against Vermont, the
court concluded that Vermont’s proposed program was illegal
and that based on the MEDS Act and the MMA it is clear that
certification of drug reimportation depends solely on the
discretion of the HHS Secretary. 73
In 2006, in Montgomery County v. Leavitt, Montgomery
County, Maryland sought a waiver from the FDA, under the
MMA, allowing its residents to import drugs from Canada. 74
Unlike the claim from Vermont, 75 Montgomery County claimed
it was entitled to a waiver simply because its residents were
paying too much money for prescription drugs. 76 In a letter to
HHS Secretary Mike Leavitt, County Executive Douglas Duncan
claimed that residents of the county were forced to “‘choose
between their health and putting food on the table’” 77 and that it
is “fundamentally unfair that people living in Canada pay a
fraction of what Americans pay for the same prescription.” 78
The FDA denied the waiver application on the basis that it
would be virtually impossible for a foreign wholesaler to meet
all the requirements of the FDCA. 79 Moreover, the Agency felt
that it would be deceptive and dangerous to allow the
importation of drugs that American consumers believed to have
originated in Canada, when actually many of these drugs
“originate from other countries such as India and Costa Rica.” 80
In addition, Montgomery County claimed that since the FDA
had often failed to enforce provisions of the FDCA the result is
a de facto waiver for drug reimportation. 81 Once again, the
court disagreed and found that the FDA has “absolute
72
73
74
75
76

Id. at 478.
Id. at 478-79.
Id. at 507.
Vermont v. Leavitt, 405 F. Supp. 2d at 470.
Montgomery County v. Leavitt, 445 F. Supp. 2d 505, 507 (D. Md.

2006).
77
78
79
80
81

Id.
Id.
Id. at 508.
See id. at 507.
Id. at 512.
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discretion” whether or not to prosecute or enforce a particular
provision. 82 Furthermore, the court affirmed the HHS
Secretary’s sole discretion as to whether to grant waivers and
stated that based on the language of the legislation there is no
issue for judicial review. 83 The Montgomery County court, like
the court in Vermont v. Leavitt, found that changes to drug
reimportation must be made by Congress since the HHS
Secretary’s actions were in accordance with all relevant
legislation. 84 Significantly, these cases solidified the role of the
FDA and the HHS Secretary as the gatekeepers to drug
reimportation.
II. WHY IS THERE A PRICE DIFFERENTIAL?
There are several reasons why brand name prescription
drugs are more expensive in the United States, though experts
disagree on which reasons wield the most influence. 85 Drug
companies often cite “research and development” of new drugs
as the most important reason for soaring drug prices. 86 In 2001,
brand name drug companies spent over $30 billion on research
and development. 87 Although developing even one new drug
takes an average of eleven years and costs over $800 million, an
independent study showed that 65% of the new drugs approved
by the FDA from 1989 to 2000 “contained active ingredients
already present in products available on the market,” 88 which
indicates “that the industry has not introduced many new and
innovative drugs to the market.” 89
82

Montgomery County v. Leavitt, 445 F. Supp. 2d 505, 512 (D. Md.

2006).
83

Id. at 514.
Id. at 516.
85
Farin Khosravi, Price Discrimination in the United States: Why Are
Pharmaceuticals Cheaper in Canada and Are Americans Seizing
Opportunities Across the Border?, 9 L. & BUS. REV. AM. 427, 429 (2003).
86
Id.
87
Id.
88
Id.
89
Id.
84
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Advertising poses another significant expense for
pharmaceutical companies. 90 The average pharmaceutical
manufacturer spends 27% of their total revenues on “marketing,
advertising and administration.” 91 Most companies commit a
greater number of employees to marketing than to research
activities. 92 For example, the top nine brand name drug
manufacturers employed on average 81% more people in their
marketing departments than in research and development. 93
Moreover from 1995 to 2000, “research personnel in these nine
companies declined by 2 percent, while marketing staff
increased by 59 percent.” 94
Executives in pharmaceutical companies are also often paid
significantly more than their counterparts in other industries. 95
In 2001 the average annual income of the highest paid executive
at the nine major pharmaceutical manufacturers was nearly $21
million, not including unexercised stock options which averaged
$48 million in 2001 alone. 96
Further, pharmaceutical manufacturers are required to give a
24% discount to the four largest federal customers 97 and drug
manufacturers are similarly mandated to give discounts to
Medicaid per the Omnibus Reconciliation Act of 1990
(“OBRA”). 98 These discounts shift the cost to other consumers
via increased prices as the manufacturers look to recover lost
profits from their discounted sales. 99
American consumers face the additional obstacle created by
price regulation policies of foreign countries, including
Canada. 100 In order to control drug prices some countries will
90

Khosravi, supra note 85, at 431.
Id. at 430.
92
Id. at 430-31.
93
Id. at 431.
94
Id.
95
Khosravi, supra note 85, at 431.
96
Id.
97
Id.
98
Id.
99
Id.
100
Khosravi, supra note 85, at 432.
91
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regulate the cost of drugs. 101 Often those countries will negotiate
prices directly with the drug manufacturers that are significantly
less expensive than what the American consumer is paying. 102
Particularly frustrating about this policy to many Americans is
that they feel as though they are subsidizing the cost of
prescription drugs of other countries. 103
In fact, price controls are just one of the techniques the
Canadian government has used to regulate the price of drugs
within their borders. 104 In the 1960’s Canada had some of the
highest drug prices of any country. 105 In response to soaring
prices the Canadian government created a regulatory scheme that
allowed generic drugs into the marketplace prior to the
expiration of the drug patent. 106 Amid criticism that this scheme
did not allow drug companies to recover their costs for research
and development, the Canadian legislature, in 1987, “passed Bill
C-22, which gave the Canadian patent-holder an exclusive right
to market the drug for the first seven years of the patent
term.” 107 Then in 1993, Canada implemented Bill C-91 which
extended the patent term from seven to twenty years. 108
Bill C-22 created the Patented Medicine Prices Review
Board (PMPRB) “to enforce price controls on patented
medicines.” 109 The PMPRB is an independent arm of the
government that has the ability to “investigate and regulate
excessive pricing” of patented pharmaceutical drugs. 110
According to Bob Nakagawa, Assistant Deputy Minister,
Pharmaceutical Services for the British Columbia Ministry of
Health, the prices of all drugs must fit within a specific range

101
102
103
104
105
106
107
108
109
110

Id.
Id.
See discussion supra Part I.C.
Khosravi, supra note 85, at 433.
Id.
Id.
Id.
Id.
Khosravi, supra note 85, at 433.
Id.
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determined by the PMPRB. 111 Moreover, the PMRRB monitors
drug prices and has the power to lower prices and levy fines to
those charging excessive rates. 112 A drug in a “new class”
cannot be sold at a price that exceeds the median price for the
same drug in seven countries. 113 For drugs that fall into an
existing class, a manufacturer cannot set the price higher than
what is currently being charged in Canada. 114 Prices can be
raised on a yearly basis, but only at a rate that is in proportion
to the Consumer Price Index. 115
III. THE FDA’S ROLE IN PROVIDING SAFE DRUGS
The evolution of federal policy on the regulation of
pharmaceutical drugs in the United States began in 1939 in
response to numerous incidents of unsafe drugs infiltrating the
country. 116 Congress responded by directing the FDA to create a
regulatory scheme that would ensure that Americans were not
receiving drugs that would cause harm. 117 Fifteen years later
Congress expanded the scheme to ensure that the drugs were
effective as well. 118 Today, the United States has what has been
called the “gold standard” for allowing only drugs that are safe
and effective within its borders. 119
111

Bob Nakagawa, Why Canadians Pay Less for Brand-Name Drugs and
More for Generics, AARP RX WATCHDOG REPORT, Jan.-Feb. 2007, at 3.
112
Id.
113
Id. The seven countries are: France, Germany, Italy, Sweden,
Switzerland, the United Kingdom and the United States. Id.
114
Id.
115
Id.
116
Buyer Beware: The Danger of Purchasing Pharmaceuticals Over the
Internet: Hearing Before the Permanent Subcomm. on Investigations of the S.
Comm. On Governmental Affairs, 108th Cong. 227 (2004) [hereinafter
Hearings] (statement of John M. Taylor, III Associate FDA Comm’r for
Regulatory
Affairs),
available
at
http://www.fda.gov/ola/2004/
importeddrugs0722.html.
117
Id.
118
Id.
119
Statement of the U.S. Food and Drug Administration Before the
Nevada State Board of Pharmacy, (2006), available at http://www.fda.gov/
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A. Federal Regulatory System
Under the current regulatory system the FDA and state
officials oversee every step of drug manufacture and distribution
so consumers can rely on “product potency, purity and
quality.” 120 Furthermore, the FDA has several layers of
protection to shield against drug quality or effectiveness being
compromised. 121 First, per the FDCA the FDA “maintains high
standards for prescription drug approval.” 122 In order for a drug
to be approved the manufacturer must show that the product is
“safe and effective” for its prescribed use. 123 The product’s
labeling must contain proper directions for use, and the drug
must be manufactured only at certain facilities that are registered
and approved by the FDA. 124 After the drug has been approved
the particular manufacturer is required to sustain compliance
with cGMP’s “to ensure that the quality of the product is
systematically evaluated throughout the manufacturing
process.” 125 The facilities where drugs are manufactured are
also subject to random inspection by the FDA. 126 After
manufacture, the pharmacists or wholesalers responsible for
drug distribution must be “licensed or authorized by the states in
which they operate.” 127
Perhaps most relevant to the drug reimportation debate is
that there are few ways for drugs to enter the stream of

oc/opacom/hottopics/importdrugs/stmt042006.html.
120
Letter from Tommy Thompson, Secretary Department of Health and
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commerce. 128 This measure protects against counterfeit or low
quality drugs being placed into the distribution system. 129 These
safeguards protect the United States’ closed system of
manufacture and distribution. 130
Once a product leaves the closed system the FDA can no
longer assure that the product is safe and effective for its
intended use. 131 Joe McCallion, a consumer safety officer in the
FDA’s Office of Regulatory Affairs said; “If you buy drugs that
come from outside the U.S., the FDA doesn’t know what you’re
getting, which means safety can’t be assured.” 132 Advocates of
drug reimportation propose to open this closed system.
However, the substantial risks identified by the FDA combined
with the fact that HHS Secretaries past and present have opposed
opening the closed system suggest that significant legislation
allowing drug importation is unlikely.
B. Counterfeiting
Although proponents of drug reimportation claim that
safeguards in Canada will sustain the high level of security to
which Americans have grown accustomed, 133 there is evidence
to the contrary. One of the biggest risks of drug reimportation is
the potential for infiltration of counterfeit drugs into the
distribution system. 134 Due to the United States’ closed system,
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counterfeit drugs that have been an issue for other nations are
not a significant problem in the United States. 135
In 2001 the World Health Organization (“WHO”) estimated
that between eight and ten percent of the world’s prescription
drugs were counterfeit. 136 Even though counterfeiting has been a
rare phenomenon in the United States, attempts at bringing
counterfeit drugs into the country have been on the rise. 137 In
order to combat the rise in counterfeiting the FDA has devoted
more resources to preventing these products from entering the
country. 138 During the late 1990’s the FDA performed five
counterfeit drug investigations per year. 139 Since 2000 the FDA
has increased the number of investigations to twenty per year. 140
In response to increased counterfeiting, the FDA
recommends stricter licensing requirements for distributors and
implores those within the drug supply chain to refuse to do
business with people of unknown backgrounds. 141 These
recommendations are directly contrary to a drug reimportation
policy that would allow more people into the distribution
system, all of whom would be outside the capability and
authority of the FDA to monitor.
C. FDA Investigation and Enforcement
Many of the FDA’s concerns about implementing an
importation program have been buttressed by FDA “blitz
exams” and undercover investigations. During the course of
Growing Epidemic of Deadly Fakes, N.Y. TIMES, Feb. 20, 2007, at F1.
135
Meadows, supra note 132, at 2.
136
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Human Services, to Senator James Jeffords (July 9, 2001) (on file with
author), available at http://www.fda.gov/oc/po/thompson/medsact.html.
137
Protecting Consumers From Counterfeit Drugs, FDA CONSUMER
MAGAZINE, May-June 2004 at 1, available at http://www.fda.gov/fdac/
features/2004/304_drug.html.
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these investigations the FDA has gathered hard evidence that
opening our borders to imported drugs heightens the risks for
several potential problems including unapproved drugs and
products that have been improperly packaged, labeled and
stored.
In July and November of 2003 the FDA conducted “blitz
exams” which consist of examining shipments of foreign drugs
bound for the United States. 142 During a three day period at
several different mail locations across the country, the FDA
identified several problems. 143
First, of 1,153 searched shipments, 88% contained
unapproved drugs. 144 Furthermore, the FDA seized twenty-five
controlled substances, as well as drugs removed from the United
States markets due to safety concerns. 145 Finally, some drugs
were not packaged properly. 146 For instance, drugs were found
shipped in tissue paper and sandwich bags. 147
These blitzes identified several of the concerns raised with
opening up the U.S. distribution system to foreign countries,
such as labeling and storage. Often drugs imported from foreign
countries are not labeled in English. 148 This can cause
significant problems for the consumer who will not likely
understand the instructions on the label. 149
Another problem is storage. Some drugs require specific
storage conditions, like refrigeration, in order to work
effectively. 150 There is also no way to know if a particular drug
was stored properly before it arrives in the United States. In
fact, in 2003 the FDA discovered that CanaRx, a website that
ships drugs from a Canadian pharmacy into the U.S., was

142
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shipping insulin, a drug needing refrigeration, in a “manner that
did not satisfy the storage conditions specified in FDA approved
labeling, and which could potentially compromise the safety and
effectiveness of the insulin.” 151 Similarly, in Rx Depot the court
noted that the drugs obtained from Canada through Rx Depot
did not have the FDA required patient package inserts, nor were
they in FDA approved “unit of use packaging.” 152 In the United
States, this packaging is utilized to ensure “that certain drugs
received by customers arrive in designated dosages with the
approved patient package insert.” 153 These examples highlight
the concern that if drugs leave the “closed system,” once they
re-enter there will be no way for either the authorities or the
consumers to know if they have been properly stored along the
way, 154 which could compromise the drug’s effectiveness. 155
Another significant issue concerns the possible interaction of
imported drugs with other drugs a consumer may be ingesting.
This is often referred to as “drugs with clinically significant
drug-drug interactions.” 156 There have been instances where the
FDA has gone undercover and discovered that the proprietors of
these websites will sell and send a particular drug even if they
are aware that an individual is taking medication that will
combine with the new medication to have adverse effects on the
patient. 157
During the blitzes in 2003 the FDA found many “foreign

151
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Id. at 14-15.
United States v. Rx Depot, 290 F. Supp. 2d 1238, 1242 (N.D. Okla.
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157
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versions” of FDA approved drugs. 158 “Foreign versions” of
FDA approved drugs are similar to the drugs approved by the
FDA but may deviate from the FDA approved version in
“potency and purity.” 159 Moreover the FDA cannot assure the
“safety and efficacy” of these drugs because the FDA has “not
monitored the manufacturing and quality control processes of the
facility in which the product was produced.”160 These “foreign
versions” are illegal in the United States because they are not
approved by the FDA, but purport to be the same as an FDA
approved version. 161
There were at least six drugs found during the blitzes that
require professional supervision. 162 For example, APO-Warfarin
was discovered during a November 2003 blitz. 163 This is a
“foreign version” of the blood thinner, warfarin. 164 According
to the FDA, “the potency of warfarin may vary depending on
how it is manufactured, and the drug must be carefully
administered and monitored by a health professional in order to
prevent serious bleeding problems.” 165 This seized drug is
illustrative of several problems. First, since the drug was sent
from another country there is no way to ensure that the drug is
taken with a doctor’s supervision. If the drug had been
prescribed by a physician in the United States, the physician
could make certain that the patient was given only a safe
amount, necessitating another trip to the doctor for more
medication. Since this drug left the “closed system” there is also
no way for the FDA to know the exact potency of each dose
158
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since it varies depending on the manufacturer. 166
In addition to blitzes, the FDA has conducted undercover
investigations into the illegal importation of drugs from Canada,
and has found significant threats to the public health. 167 In
February and August 2004 the FDA made undercover purchases
from Canada Care, a company engaged in the importation of
drugs into the United States from Canada. 168 In this particular
undercover investigation the FDA purchased both Sporanox and
Neurontin. 169 Instead of receiving Neurontin, the undercover
agent was sent two drugs that are unapproved by the FDA,
APO-Gabapentin and Novo-Gabapentin. 170 Since the drugs
received are not approved, the FDA cannot “assure the safety
and efficacy” of these drugs. 171 Furthermore the FDA has no
information on how the drugs are made, what information is
included with the drug or possible side effects of the drug. 172
Thus, the drugs are “more likely to be contaminated,
counterfeit, inherently ineffective, or contain different amounts
of the active ingredients from similar drugs that have been
reviewed and approved by the FDA.” 173
The shipment of Sporanox did contain the FDA approved
version of the drug, but the method of shipment caused the FDA

166

Press Release, Food and Drug Admin., Recent FDA/U.S. Customs
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to consider it a “potentially serious health threat.” 174 Normally
Sporanox is taken in one week “pulses.” 175 Patients then wait
three weeks before continuing with another “pulse” treatment. 176
In between the “pulses” a patient is supposed to consult with his
doctor to determine whether the treatment should continue or
terminate. 177 Termination would be due to the patient
experiencing side effects that could potentially damage his heart
or liver. 178 The Canadian pharmacy sent the undercover agent
three packages of Sporanox, potentially allowing the patient to
consume two “pulses” without consulting a physician in
between. 179 This could result in serious side effects, including
fatality. 180 Accordingly, in Rx Depot, the court found that
“[p]rescription drugs obtained through Rx Depot frequently are
dispensed in greater quantities than are requested by the
prescribing physician.” 181 Additionally, Rx Depot dispensed
drugs in preset amounts regardless of the patient’s prescribed
quantity, and “without directions to take the drug for only the
number of days prescribed by the U.S. physician.” 182 The
findings of this undercover investigation are particularly
significant because legalizing drug reimportation could lead to
the exact consequences the FDA fears. If citizens are allowed to
legally import drugs from Canada, or other countries, the drugs
they receive will be outside the FDA’s regulatory scheme and
this could lead to dangerous consequences.
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IV. STATE PROGRAMS
The clamoring for an importation program has come largely
from state governors looking for ways to save money and satisfy
citizens frustrated by high drug costs. As noted in Part II,
several states, including Minnesota and Wisconsin, have
established websites that will link citizens to websites selling
drugs from Canada. 183 Unfortunately some of these programs
have not worked as effectively as the state governments had
hoped. In fact, in many instances, these programs have
demonstrated the importance of sustaining the closed distribution
system. 184
Research by the state of Minnesota exposed several problems
with how drugs are distributed and produced in Canada. 185
During a pre-announced visit to Canada, Minnesota officials
noticed that many pharmacies used “unsupervised technicians,
not trained pharmacists, to enter medication orders and to try to
clarify prescription questions.” 186 Furthermore one of the
pharmacies the officials visited had its pharmacists “review 100
new prescriptions or 300 refill prescriptions per hour, a volume
so high it would have been impossible to assure safety.” 187 The
issue of proper labeling 188 was not a priority for at least one
pharmacy who did not label any of its products, choosing
instead to send the labels along unattached, even to those
customers who were receiving more than one prescription. 189
Even more troubling, the Minnesota officials noted that many
products that required refrigeration were being shipped unrefrigerated. 190
Moreover, the state of Wisconsin had similar problems when

183
184
185
186
187
188
189
190

Hearings, supra note 116.
See id.
Id.
Id.
Id.
See supra Part III.C.
Hearings, supra note 116.
Id.

DEVIN.DOC

7/1/2007 11:05 PM

IMPORTING A HEADACHE

1445

it reviewed reports presented by the three Canadian pharmacies
it linked to via its website. 191 Wisconsin officials found that 361
of the 765, or 41%, of the prescriptions filled by the Canadian
pharmacies violated the terms of the agreement made between
the pharmacies and the state. 192 “Specifically, 127 of the
dispensed drugs were products not approved by FDA or
available in the U.S., while 189 of the drugs were products not
authorized by the state program.” 193 Additionally, in six
instances the pharmacies mistakenly sent drugs that required
refrigeration in the mail. 194 The state of affairs became so
drastic that the Wisconsin Department of Health and Family
Services mailed letters to all three pharmacies demanding they
stop these practices. 195 Even more revealing is this statement
from the executive director of the Wisconsin Pharmacy Society:
“no one in Wisconsin has any real idea what these Canadian
businesses are doing.” 196
These studies are significant because many proponents of
drug reimportation maintain that Canadian safety measures are
on par with the best in the world. 197 In addition to the findings
of both Minnesota and Wisconsin, in August 2005 the FDA
performed an investigation at airports in New York, Los
Angeles and Miami “which found that nearly half of the
imported drugs the FDA intercepted from four selected countries
were shipped to fill orders that consumers believed they were
placing with ‘Canadian pharmacies.’” 198 It turned out that 85%
191
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of the drugs being promoted as “Canadian” actually came from
27 other countries around the world. 199 The findings of this
investigation drive home the importance of sustaining a closed
distribution system and indicate that many internet sites that
claim to be “Canadian” are in fact selling drugs of unknown
“origin, safety and efficacy.” 200
When officials from New Hampshire Governor Craig
Benson’s office traveled to the on site location of
CanadaDrugs.com they found conditions that were later termed
“significant safety issues.” 201 Moreover as part of the “terms of
service” for this site “purchasers . . . agree that they ‘will not
be liable for damages arising from personal injury or death’
from the use of drugs sold by the pharmacy.” 202 As a result a
consumer would have no remedy vis a vis CanadaDrugs.com for
“injuries arising from the use of drugs from this shipper.” 203
Presumably the lack of legal remedy would lead to the increase
in insurance. This is significant because the biggest advantage
drug reimportation is purported to have is the opportunity to
save Americans money. The ability of importation to save
Americans money is one of the two considerations the HHS
Secretary is mandated to take into account when considering
whether to implement drug importation per the MMA. 204
Therefore an increase in insurance costs could potentially
mitigate any savings a comprehensive drug reimportation plan
would bear.
V. THE PHARMACEUTICAL LOBBY
The pharmaceutical industry has used its vast resources,
including spending a significant amount of money on political
available at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01441.html.
199
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donations, to influence politicians and hire lobbyists to advocate
on its behalf. 205 The pharmaceutical industry has achieved
significant legislative victories, as seen in the Medicare
Modernization Act of 2003 and patent extensions, and the
industry is expected to fight importation with the same vigor. 206
A. Pharmaceutical Industry Resources
The pharmaceutical lobby has been called an “elephant
among chickens” 207 because of its influence and ability to
achieve its desired results. 208 In fact, pharmaceutical
manufacturers spend money on lobbying efforts and campaign
contributions at a rate that exceeds almost any other industry. 209
In 2003 the pharmaceutical industry’s trade group, The
Pharmaceutical Research and Manufacturers of America
(“PhRMA”) spent $8.5 million on lobbying. 210 Furthermore,
several PhRMA members have their own lobbying budget in the
millions of dollars. 211 For instance, in only the first six months
of 2003 Eli Lilly and Co. spent $2.9 million on lobbying
services, Bristol-Myers Squibb spent $2.6 million, Johnson &
Johnson $2.2 million, Hoffmann-LaRoche $2 million and Pfizer
$1.8 million. 212 In sum, the pharmaceutical industry spent over
$29 million in the first half of 2003, when the drug
reimportation debate was at its apex. 213 From 1998 to 2004
pharmaceutical and health care product companies spent more
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than $675 million on federal lobbying. 214 This figure exceeded
the industry with the second most expenditures by almost $80
million. 215 Moreover, these figures do not take into account the
money spent on campaign contributions from these companies
and their Political Action Committees (“PAC”). 216
During the 2003-2004 election cycle, the pharmaceutical
industries combined expenditures on campaign contributions and
lobbying was $818 million; second most of any industry. 217 In
the 2003-2004 election cycle, Pfizer’s PAC contributed
$2,261,777 to various candidates and committees. 218 In the
2005-2006 cycle that number rose to $3,241,156. 219 In addition,
Eli Lilly’s PAC contributed $1,678,376 in 2003-2004 and an
additional $1,565,336 in 2005-2006. 220 These numbers are
particularly significant considering federal election law only
allows a PAC to contribute $5,000 dollars each election cycle to
any particular candidate. 221
The pharmaceutical industry provides politicians with
additional benefits beyond just campaign donations. In addition
to the $161,000 that Senator Joe Lieberman received in
campaign donations from 1993 up to his vice-presidential run in
2000, Lieberman also flew on Pfizer’s corporate jet and made a
speech before PhRMA’s membership. 222 The pharmaceutical
industry paid for events at both the Democratic and Republican
conventions in 2000, including a “Mardi Gras-style gala” on the
sets of Paramount studios in Los Angeles for the Democratic
214
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convention. 223 The industry also contributed $625,000 to the
Bush-Cheney inaugural committee. 224 Industry companies paid
for tens of millions of dollars worth of television and radio ads
on behalf of a non-profit group that was attacking President
Clinton’s proposal for a “government-run prescription drug
program.” 225
B. Industry Manpower
Not only does the pharmaceutical industry have significant
resources, but it uses those resources to wield a great deal of
influence. In 2004 PhRMA hired former Congressman Billy
Tauzin to become the president and CEO of its organization. 226
This hire was particularly controversial and drew the ire of
Democrats and public advocacy groups, because Tauzin was
being considered for the job while he was still chairman of the
House Energy and Commerce Committee, which has
“regulatory oversight of the pharmaceutical industry.” 227
Furthermore, Tauzin and the committee he chaired played a
critical role in constructing the Medicare Modernization Act of
2003 228 which has been lauded as a rousing success for the drug
industry. 229
In 2001 more than half of the pharmaceutical industry’s 625
lobbyists were former members of Congress, former
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Congressional staff members and former government
officials. 230 Former Secretary of Defense Donald Rumsfeld was
once chief executive at the drug company G.D. Searle.231 Not
only are there hundreds of pharmaceutical lobbyists, but they are
also broadly dispatched. The drug industry lobbied at least 1,600
bills from 1998-2004. 232
C. Industry Influence and Victories
As illustrated above the pharmaceutical industry spends a
great deal of money with the intent of influencing politicians and
political candidates. Of course, these companies would not
consistently dole out millions of dollars if these tactics were
ineffective. The pharmaceutical lobby began in earnest in the
1960’s after the creation of Medicare and gained widespread
attention for its efforts and influence in defeating President
Clinton’s health care plan in the 1990’s. 233 Perhaps the effort
that best demonstrates the pharmaceutical lobby’s ability to
wield influence is its lobbying of the Medicare Modernization
Act (MMA) of 2003. That legislation, which went into effect in
2006, created a prescription drug benefit for seniors that was
funded by taxpayer dollars. 234 The remarkable aspect of the bill
is that despite the fact that it created a reliable market of 41
million customers 235 for the pharmaceutical industry, there was
still a provision in the bill that prohibited the government from
negotiating lower prices with pharmaceutical companies. 236
This provision was not included in the MMA to prevent drug
230
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companies from losing money because drug companies actually
stand to make a huge profit. 237 Analysts at Goldman Sachs
predict that the MMA will result in a 9% increase in profits for
drug companies. 238 This percentage represents $13 billion per
year. 239 Furthermore, a Boston University study on the impact
of the MMA predicted that 61% of the Medicare money spent
on prescription drugs will turn directly into profit for the drug
companies. 240 In addition, the study predicts that drug
companies will see increased profits of $139 billion over an
eight year period. 241 The positive impact the MMA will have on
drug industry profits demonstrates the success of the industry’s
lobbying efforts. In fact, Helen Savage of the North Carolina
state office of AARP said, “[t]he lack of effective cost
containment or price controls for prescription drugs in the
Medicare Modernization [of 2003] reflects the strength of the
pharmaceutical lobby.” 242
Perhaps as significant as what the drug companies gained via
the passage of the MMA is what they avoided. Despite polls that
showed a majority of Americans supported drug reimportation, a
provision allowing full scale importation was not included in the
MMA. 243 Moreover, other provisions the drug industry strongly
objected to were not in the bill, such as government price
controls that have proven effective in Canada for reducing drug
prices and increased access to the marketplace for generic
drugs. 244 Both price controls and greater access to generics
would likely have the effect of driving drug costs down, yet
237
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these provisions proved elusive. 245 Of the MMA one Republican
close to the drug industry said, “In their [drug industry] view,
by improving access for all seniors, we will ameliorate any
pressure on the industry toward price controls or
reimportation.” 246
The MMA illustrates the influence exerted by the drug
industry in Washington, and such success is not an aberration.
For instance at the end of 2001 Congress passed the Best
Pharmaceuticals for Children Act that extended patents on
certain drugs by six months. 247 The impetus for this measure
was the fear of an anthrax attack and the government’s desire to
stockpile Cipro, 248 an antibiotic used to treat anthrax
exposure. 249
Just prior to passing the Best Pharmaceuticals for Children
Act, Bayer, the manufacturer of Cipro, agreed to give the
government a 46% discount on the first 100 million doses of
Cipro sold, saving the government $82 million. 250 Not
coincidentally, the 2001 bill had provisions that were favorable
to Bayer. 251 In fact, the bill permitted a six month extension on
certain drug patents, including Cipro, in return for drug
companies performing tests on these drugs to ensure their safety
and efficacy in children. 252
Some groups have argued that safe use for children should
be part of the FDA approval process in the first place, before a
drug can be obtained in the marketplace. 253 Additionally, the
245

Id.
Id.
247
S. 1789 § 7, 106th Cong. (2001) (enacted).
248
See Patently Offensive: Congress Set to Extend Monopoly Patents for
Cipro and Other Drugs, Public Citizen, http://www.Citizen.org/
print_article.cfm?ID=6435.
249
Wayne, supra note 224.
250
Cipro Saga Exposes how Drugmakers Protect Profits, USA TODAY,
Oct. 29, 2001.
251
See Connolly, supra note 237.
252
S. 1789 § 7, 107th Cong. (2001) (enacted).
253
Patently Offensive: Congress Set to Extend Monopoly Patents for
Cipro and Other Drugs, Public Citizen, http://www.Citizen.org/
246
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amount of money drug companies gain through patent extension
greatly exceeds the amount of testing. 254 According to a study
performed by the Tufts Center for the Study of Drug
Development, pediatric testing costs an average of $3.87 million
per drug. Per this legislation the FDA requested testing on 188
drugs, putting the total cost of testing at $727 million. 255 The
patent extensions were expected to give patent holding
companies an additional $29.6 billion in additional sales,
handing each company an additional $592 million per year in
added profits. 256 Thus, the amount in added sales is forty times
the cost of testing, 257 a veritable windfall for the drug
companies. Eli Lilly and Company was able to make an
additional $900 million in revenue on the anti-depressant,
Prozac, because of the six month patent extension. 258 In
addition, Bayer stood to gain an additional $358 million thanks
to the extension. 259 Thus, Bayer would recover all of their $3.7
million in lobbying expenses from 1999-2001 in a mere two
days. 260 Not surprisingly, the bill’s sponsors, Senator Chris
Dodd and Senator Mike DeWine, received the third and seventh
highest contributions, respectively, from drug companies among
senators from 1990-2000. 261
The losers in this political exchange are U.S. consumers.
The longer drug patents are extended, the longer cheaper,
generic manufacturers are excluded from the marketplace. 262
This particular patent extension cost consumers $14 billion over
print_article.cfm?ID=6435.
254
Id.
255
Id.
256
Id.
257
Id.
258
Maureen Groppe, Departing Congress Treated Drug Companies Well,
GANNETT NEWS SERVICE, Nov. 28, 2002.
259
Patently Offensive: Congress Set to Extend Monopoly Patents for
Cipro and Other Drugs, Public Citizen (2001), http://www.Citizen.org/
print_article.cfm?ID=6435.
260
Id.
261
Id.
262
See Wayne supra note 224.
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what generics would have cost. 263
Protecting and extending patents is one of the primary goals
of the pharmaceutical industry and it has been very effective in
getting results. In 2003, the World Trade Organization was
forced to appease the drug industry because the Bush
administration, fiercely supporting the industry, would not sign
an agreement that may have compromised drug industry profits,
even in the face of desperate need for humanitarian aid.264 In the
face of AIDS, malaria and tuberculosis epidemics in Africa, the
WTO tried to respond with worldwide agreement to get less
expensive drugs to those in Africa who badly need them. 265 The
United States government rejected the initial proposal, saying
that the agreement should be limited to only a small number of
countries and apply to only a few diseases. 266 The rationale for
this position was that impoverished nations would somehow
exploit multi-national drug companies, whose profits are among
the largest in the world. 267 Every other country that was home
to a major pharmaceutical company was willing to sign the
agreement. 268 In fact, an Indian pharmaceutical company, Cipla,
was willing to sell AIDS drugs to African countries for 4% of
the price charged by multi-national companies. 269 The final
agreement included the Bush administration’s demands that
“generic medicines could be imported to cure any lifethreatening disease, so long as it was a public health
emergency” and provisions that would ensure countries would
not take advantage of the reduced costs for commercial profit

263

Wayne, supra note 224.
Elizabeth Becker, Cheaper Medicines for World’s Poor; Trade Rules
Altered on Patented Drugs, INT’L HERALD TRIB., Sept. 2, 2003 at 1.
265
Id.
266
Id.
267
See Id.
268
Becker, supra note 264.
269
Aravind Adiga, Prescription For Profits; India’s generic-drug makers
are flooding international markets with cheap copycat pills, infuriating
behemoth rivals from the U.S. and Europe, TIME ASIA, Sept. 22, 2003, at
44.
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instead of meeting public health needs. 270
Critics railed against the United States accusing the Bush
administration of including too much “bureaucratic red tape”
that would “doom” the effective implementation of the
agreement. 271 Ellen Hoen of Doctors Without Borders said the
“deal was designed to offer comfort to the U.S. and the Western
pharmaceutical industry. Unfortunately, it offers little comfort
for poor patients. Global patent rules will continue to drive up
the price of medicines.” 272
The drug industry’s relationship with the federal government
has serious health implications besides those in Africa. For
instance, in 1992 the Prescription User Fee Act streamlined the
process of bringing life-saving drugs into the marketplace, with
the condition that companies are required to perform follow up
studies to prove that these drugs are safe. 273 Additionally in
1997, Congress passed the FDA Modernization Act, which
lowered the standards for approving new drugs. 274 Some drugs
were only required to be tested in one clinical trial “to show that
the drug was reasonably safe and effective.” 275
Both pieces of legislation were helpful to the drug industry
but have proven problematic in practice. Marcia Angell, M.D.,
a former editor in chief of the New England Journal of
Medicine, called the FDA Modernization Act, “a bundle of gifts
to the pharmaceutical industry.” 276 Angell went on to say,
“[a]mong other gifts was a dropping of standards for approving
new drugs.” 277 The consequences of reduced standards have
been severe. For instance, Merck’s painkiller Vioxx is estimated
270
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to have caused 140,000 heart attacks and 55,000 deaths in the
United States. 278 Additionally, many drug companies are not
performing the follow up tests that are required by law and the
FDA simply does not have the resources to ensure the tests take
place. 279 A study performed by Congressman Ed Markey’s
office found that half of the post marketing studies that should
have begun, have not started, despite the fact that companies
have been selling the drugs for an average of twenty months. 280
In one instance the companies had been selling the drug for six
years and nine months with no testing. 281
The FDA does not have the resources to monitor drug
companies at the rate with which they are able to get drugs
approved. 282 For example, Pfizer’s revenue went from $11.3
billion in 1996 to $52 billion in 2004. 283 On the other hand the
FDA’s budget was only $1.7 billion in 2004. 284 Moreover, in
2005 the FDA employed 11,000 people, only a slight increase
from the 8,200 that were employed by the agency twenty-five
years ago. 285 Thus, the great disparity in resources only serves
to exacerbate the effectiveness in getting drug companies the
results they desire.
Furthermore, given the FDA’s limited resources, it is
difficult to understand how an expanded regulatory scheme, via
drug reimportation would be viable. Even if proponents of drug
reimportation are willing to sacrifice some degree of safety in
return for a reduction in prices, without a significant and
probably costly expansion of FDA resources, it seems likely that
comprehensive drug reimportation would rely almost solely on
the safety provisions of other countries. Although there are no
reported instances of Americans being injured due to
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consumption of Canadian pharmaceuticals, the idea of relying on
another country to provide millions of American citizens with
drugs is a daunting proposition.
It seems clear that the “worst case scenario” of drug
reimportation would involve evil doers infiltrating a foreign drug
source and importing drugs to America. In one of the stranger
ploys by the pharmaceutical industry, PhRMA was reported to
have attempted to commission a fiction novel designed to scare
people away from drug reimportation. 286 PhRMA even admits to
considering the idea, but says they ultimately decided against
funding the project. 287 The novel was going to involve a
terrorist organization that uses Canadian pharmaceutical websites
to murder millions of American customers. 288 Kenin Spivak,
who was to co-write the abandoned project said, “they wanted
lots of people to die.” 289 Although playing on people’s worst
fears to curry political favor in such a clandestine manner is
abhorrent, the prospect of opening America’s borders to drugs
of unknown sources just five years removed from terrorist
attacks on U.S. soil and with counterfeiting on the rise 290 is
unnerving. Even without PhRMA support, the novel is due out
next year 291 and although it is a work of fiction, opening the
“closed system” seems to at least make the premise a real life
possibility.
VI. LOOKING AHEAD
As the 2008 presidential election nears, solutions to high
drug costs will likely receive greater public attention. In fact,
legislation passed at the end of 2006 that allows Americans to
carry a moderate amount of drugs into the United States from
286
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287
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Canada should raise the temperature of the debate. 292 In
addition, the results of the 2006 mid-term elections have left
some reimportation supporters optimistic that a comprehensive
reimportation plan may be implemented. 293 However, these
reimportation advocates may be disappointed, as there remains
the possibility that legislators will instead focus their efforts on
modifying the MMA as a means of reducing drug costs. 294 Even
if modification of the MMA is unsuccessful there remain several
alternatives that do not include the importation of drugs from
foreign countries. 295
A. 2007 Homeland Security Appropriations Bill
In the fall of 2006, Congress passed the 2007 Homeland
Security appropriations bill which included a provision that
would allow Americans to personally transport as much as a 90
day supply of FDA approved drugs from Canada. 296 This
measure has been lauded as indicative that more meaningful
drug reimportation is inevitable, prompting Congressman David
Vitter to say, “[n]ow it is only a matter of time before we pass a
comprehensive drug reimportation bill.” 297 Although it is true
that this provision allows drugs to be legally imported from
Canada, Congressman Vitter’s rhetoric is overly simplistic.
First, this legislation only allows an individual to personally
292

See 2007 Homeland Security appropriations bill, Pub. L. No. 109295 § 535 (2006).
293
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535 (2006).
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purchase their drugs in Canada. 298 The only citizens that will
benefit in a meaningful way are those that live close enough to
Canada to make traveling across the border more cost effective
than simply buying drugs in the United States. Particularly
ironic is that Congressman Vitter is a Representative of the State
of Louisiana, a state so far from the Canadian border 299 that it is
hard to imagine a trip to Canada for a 90 day supply of drugs
being cost effective for any resident of that state.
Moreover, those most in need of prescription drugs, senior
citizens, may not benefit from this legislation because the bill
requires an individual to personally purchase the drugs in
Canada. 300 It seems likely that many senior citizens will be
physically unable to travel north to purchase drugs.
Furthermore, there will inevitably be a group of people who find
it inefficient to travel to Canada to buy drugs for only a 90 day
supply. Although this legislation will certainly help some people
gain access to cheaper drugs in Canada, the scope of this
legislation is very narrow and can hardly be considered
suggestive that full scale drug reimportation for the entire
country is imminent.
Additionally, as previously discussed, the drug industry has
demonstrated the ability to make small concessions in order to
achieve its overall goals. 301 This kind of savvy was seen in their
handling of the MMA, patent extensions and in dealing with the
WTO. 302 Thus, there is good reason to be skeptical that proreimportation members of Congress will be successful in
asserting their agenda. A more comprehensive reimportation
program would inevitably be met with massive resistance by the
drug industry and would involve overcoming all the hurdles
already discussed. 303
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B. 2006 Mid-Term Elections
The 2006 mid-term elections gave Democrats a majority in
the House and Senate 304 and have left many importation
advocates feeling optimistic about the prospects for a
comprehensive reimportation plan. 305 Democrats have tried to
strengthen their position for implementing drug reimportation by
adding reimportation advocates, Senators Sherrod Brown, Bernie
Sanders and Barack Obama to the Senate Health Committee. 306
Although Democrats view reimportation more favorably than
Republicans, Democrats hold only a slight majority in both
houses of Congress and any comprehensive plan could be vetoed
by President Bush, who has consistently been against
reimportation because of the safety concerns expressed by the
FDA and HHS Secretaries past and present. 307 Of more pressing
concern to Democrats could be modification of the MMA. 308
Thus, it would be difficult for Congress to also initiate drug
reimportation considering the heavy opposition that can be
expected to both reimportation and price negotiations.
C. Modification of the MMA
In fact the prescription drug benefit included in the MMA,
known as Part D, 309 may be ripe for modification and could
304
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WASH. POST, Nov. 11, 2006, at A3.
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See Fischman, supra note 305.
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Kara Gavin, Study: Senior Medicare drug costs vary widely among
states, University of Michigan News Service, http://www.umich.edu/
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potentially quiet clamoring for importation. The success of Part
D and its ability to provide affordable drugs to those who might
otherwise favor importation will be a critical issue in whether
the importation debate gains steam or dissipates. 310 Even as
currently constituted, Part D is saving the average beneficiary
55%. 311 One of the problems with the MMA is that the cost of
drugs is distributed unevenly throughout the country. 312 A recent
study at the University of Michigan found that “the plan reduces
costs for some seniors more than others, depending on where
they live.” 313 An individual in a given state, taking the same
drugs, could be paying thousands more than someone in a sister
state. 314 For instance the study found that depending on what
medicines one might be taking and the individuals enrollment
plan, a person in one state may pay 10 percent of their annual
income “for prescription drug coverage and premiums and copays, while someone taking the same medicines in another state
would spend 20 percent of their income.” 315 The study also
concluded that cost of living had no impact on disparate drug
prices. 316 In fact the researchers found that those in poorer parts
of the country were generally paying more than others. 317
Matthew Davis, M.D. who led the study said “[t]his has
implications for individuals’ ability to afford and keep taking
their medicines, and for policy as the prescription drug benefit is

BURLINGTON FREE PRESS, April 24, 2007.
310
See Seay, supra note 4.
311
Ceci Connolly, Drug Benefit Disparities Cited, WASH. POST, April
19, 2005.
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states, University of Michigan News Service, http://www.umich.edu/
~urecord/0607/Jan22_07/18.shtml.
313
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evaluated and changes are considered.” 318 Davis went on to
state, “[n]o one doubts that the Part D benefit has helped many
seniors by giving drug coverage to those who previously had
none, but the level of variation among the lowest-cost plans is
far greater than many seniors and policymakers probably
anticipated.”
The need for reform is clear considering drug manufacturers
increased prices by 6.2% in 2006. 319 General inflation was
3.2%. 320 The increase comes on the heels of a six year period
where brand name drugs increased by 54%, compared to a
general inflation rate of 20%. 321 On the other hand the Medicare
prescription drug benefit has been credited with increasing drug
sales in the U.S. by 8.3% in 2006 by providing coverage to
those were “previously uninsured or underinsured.” 322 Thus, the
drug benefit has led to improvements and some cost savings, but
there is room for more.
Reform has been on the minds of policy makers, as some in
Congress are eager to pass legislation allowing Medicare to
negotiate prices with drug companies. 323 Presently, commercial
insurers negotiate drug prices with pharmaceutical manufacturers
and “set their own drug lists, premiums and co-pays.” 324
A bill 325 sponsored by Congressman John Dingell would
change the current system and allow the HHS Secretary to
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negotiate lower drug prices with drug manufacturers. 326 While
critics contend that the bill is toothless because it doesn’t allow
the Secretary the authority to limit the drugs covered by
Medicare, a technique used by private insurers to get discounts,
at least one proponent of the bill has argued that even if this is
true at least the “secretive process of drug price setting will be
exposed to public scrutiny.” 327
D. Potential Solutions to Reducing Drug Prices
Other legislative efforts could be geared toward allowing
generic drugs easier entry into the marketplace. Drug companies
have been able to exploit a loophole in the current law that
allows them to exclude generics from competing with their
brand name drugs. 328 Sources at the FDA have indicated that
drug companies are misusing “citizen petitions” 329 to prevent
generic competition for longer than Congress intended. 330
Merely filing a petition initiates a review of the generic version
of the drug by the FDA. 331 The process often takes months, or
even years to complete. 332 FDA Chief Counsel Sheldon
Bradshaw said these petitions, “appear designed not to raise
timely concerns with respect to the legality or scientific
soundness of approving a drug application, but rather to delay
approval by compelling the agency to review arguments that
could have been made months before.” 333 One estimate indicates
that a citizen petition, filed by the drug manufacturer Biovail
326
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Corp., delaying the introduction of a generic version of
Wellbutrin to the marketplace is costing consumers $37 million
per month. 334
In an effort to facilitate the expansion of generic drugs,
Senators Lott and Stabenow introduced legislation in the 109th
Congress that would have allowed consumers earlier access to
generic drugs and closed the “citizen petition” loophole. 335 The
legislation remained in Senate committee in the last Congress
and has yet to be re-introduced in the 110th Congress. This
issue has been the subject of reform efforts since the late
1990s 336 and thus it seems likely to once again be the subject of
legislative debate.
A bill 337 currently before the Senate, sponsored by Senator
Byron Dorgan and supported by members of both parties, would
allow U.S. customers to order prescription drugs from nineteen
countries around the world. 338 The pharmaceutical industry
immediately voiced its objection to the bill, with Tauzin
reminding members of Congress of the serious threat
counterfeiting poses and citing the Medicare prescription drug
benefit as a source of reduced drug prices. 339 Additionally, a
2004 study by the Congressional Budget Office indicates that
importation from foreign countries would save U.S. consumers
only one percent over a ten year period and that a program that
allowed importation only from Canada “would produce a

334
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negligible reduction in drug spending.” 340
A potential complication to drug importation is the Canadian
government’s threat to ban the bulk export of prescription
drugs. 341 In July, 2005 Canada’s health minister, Ujjal Dosanjh
said “[w]e will enhance and systemize our drug-supply
monitoring activity, and if necessary we will use export control
to protect human health and our nation’s drug supply.” Later
that same year Dosanjh told a Harvard Medical School audience,
“[i]t is difficult for me to conceive of how a small country like
Canada could meet the prescription drug needs of approximately
280 million Americans without putting our own supply at
risk.” 342 He also stated that Canada “cannot be the drug store of
the United States.” 343 Despite Dosanjh’s explanation, Senator
Dorgan blamed another culprit saying, “[t]his demonstrates the
strength and the reach of the pharmaceutical industry,” noting
that drug companies have tried to limit the amount of drugs they
supply to Canada to “discourage the sale of those drugs to U.S.
consumers.” 344 In fact, seven pharmaceutical companies have
reduced their supply of drugs to Canadian companies who sell to
U.S. customers. 345 Thus far, Canadians have not felt the effects
of this reduction in medications thanks to stockpiling by
Canadian pharmacists, but this is only a short term solution. 346
If Canada does place greater restrictions on the export of drugs
to the United States it would be damaging to the state plans

340
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described earlier. 347 In fact, in response to the Canadian threat
the state of Illinois began exploring opportunities to import
pharmaceuticals from Belgium and France. 348 Additionally,
Rhode Island Secretary of State Matt Brown said reduced access
to the Canadian market “would totally undermine our
program.” 349 Therefore, the reaction of the Canadian
government to U.S. importation efforts will be an important
factor in the success of state and federal importation programs.
One avenue of compromise that has received less attention is
the possibility of passing legislation that would prevent drug
companies from advertising on television and radio. Since drug
companies spend 27% of their revenue 350 and approximately $4
billion per year 351 on direct to consumer advertising (“DTCA”)
any reduction in those numbers would likely lead to a decrease
in pharmaceutical costs 352 to the U.S. consumer. Legislation of
this kind is not unprecedented. 353 In the early 1970’s Congress
passed legislation banning the advertisement of cigarettes on
television or radio. 354 In order to satisfy first amendment
safeguards protecting restrictions on commercial speech the
government “must assert a substantial interest to be achieved by
its restriction and employ a regulatory technique in proportion to
that interest.” 355 There is a strong argument that television
advertisements for pharmaceutical drugs are harmful and that the
only way to protect patient safety is to ban such advertisements.
347
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Direct to consumer advertising can result in the public desiring
newer drugs that are not as effective as drugs that have been in
the market much longer. 356 When combined with the FDA’s less
rigorous drug approval process and lack of follow up testing, 357
newly advertised drugs can have dangerous consequences.
Perhaps the best example is the aforementioned heart attacks and
deaths caused by Vioxx. 358 One study on direct to consumer
advertising found that “more advertising leads to more requests
for advertised medicines, and more prescriptions. If DTCA
opens a conversation between patients and physicians, that
conversation is highly likely to end with a prescription, often
despite physician ambivalence about treatment choice.” 359
Perhaps that is why the United States is one of only two
countries that allows direct to consumer advertising. 360
Moreover, as the tragic consequences of the Vioxx episode
demonstrate, it is also likely that physicians will prescribe
requested advertised drugs even if more effective treatments
exist. 361 In 2005, there was legislative action to limit the amount
of television and radio advertising of prescription drugs, but
those proposals did not make it out of House committee. 362
Neither of the previous proposals goes as far as banning
television and radio advertisements of prescription drugs, but it
seems clear that an effort to do so would not only increase
patient safety but would also create more affordable drugs for
U.S. consumers. 363
356
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CONCLUSION
There is no doubt that soaring prescription drug prices must
be remedied. However, that remedy should not require
jeopardizing the safety of prescription drugs or opening our
borders to products of unknown sources. The findings of the
FDA, HHS Secretaries past and present, some state governments
and others indicates that there are legitimate risks in
implementing a full scale drug reimportation plan. Although
there is optimism that the current political and economic
landscape will result in drug reimportation being passed, the
reality is that drug companies have gained desirable results for
decades. Alternatives to drug reimportation exist and they should
be thoroughly explored before we expose ourselves to the risks
reimportation entails.
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